HRP20192080T1 - Terapeutske fuzije nukleaza-albumine i postupci - Google Patents
Terapeutske fuzije nukleaza-albumine i postupci Download PDFInfo
- Publication number
- HRP20192080T1 HRP20192080T1 HRP20192080TT HRP20192080T HRP20192080T1 HR P20192080 T1 HRP20192080 T1 HR P20192080T1 HR P20192080T T HRP20192080T T HR P20192080TT HR P20192080 T HRP20192080 T HR P20192080T HR P20192080 T1 HRP20192080 T1 HR P20192080T1
- Authority
- HR
- Croatia
- Prior art keywords
- albumin
- variant
- fragment
- domain
- polypeptide according
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102000009027 Albumins Human genes 0.000 claims 21
- 108010088751 Albumins Proteins 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 101710163270 Nuclease Proteins 0.000 claims 16
- 239000012634 fragment Substances 0.000 claims 15
- 108010071390 Serum Albumin Proteins 0.000 claims 8
- 102000007562 Serum Albumin Human genes 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108091006905 Human Serum Albumin Proteins 0.000 claims 5
- 102000008100 Human Serum Albumin Human genes 0.000 claims 5
- 210000004899 c-terminal region Anatomy 0.000 claims 5
- 108010083644 Ribonucleases Proteins 0.000 claims 4
- 102000006382 Ribonucleases Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- 241000700199 Cavia porcellus Species 0.000 claims 1
- 102220518153 DNA-directed RNA polymerases I and III subunit RPAC1_E13R_mutation Human genes 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 101000667595 Homo sapiens Ribonuclease pancreatic Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 102220644742 Plakophilin-2_N76S_mutation Human genes 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102200062706 rs121908046 Human genes 0.000 claims 1
- 102200139516 rs35960830 Human genes 0.000 claims 1
- 102220092172 rs753180642 Human genes 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
- C12Y301/27005—Pancreatic ribonuclease (3.1.27.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (18)
1. Polipeptid koji sadrži prvu nukleaznu domenu, drugu nukleaznu domenu, i albumin, ili varijantu albumina koja ima više od 80% identičnosti s aminokiselinskom sekvencom ljudskog serumskog albumina prikazanom u SEQ ID NO: 1, ili ulomak albumina koji sadrži najmanje domenu III albumina ili domenu III albumina i dodatnu domenu odabranu iz skupine koja se sastoji od domene I, domene II i domene III, pri čemu je prva i/ili druga nukleazna domena operativno povezana s albuminom, ili njegovom varijantom ili ulomkom, proizvoljno preko poveznice, pri čemu je prva nukleazna domena RNaza i druga nukleazna domena je ljudska DNaza1 koja sadrži supstitucije aminokiselina E13R, N74K, A114F, i T205K, numeriranje aminokiselina se odnosi na SEQ ID NO: 66.
2. Polipeptid prema patentnom zahtjevu 1, naznačen time što je druga nukleazna domena operativno povezana na N-terminalni kraj albumina, ili njegovu varijantu, i prva nukleazna domena je operativno povezana na C-terminalni kraj albumina, ili njegovu varijantu, poželjno pri čemu su druga i prva nukleazna domena operativno povezane na odgovarajuće N- i C- terminalne krajeve, albumina, ili njegovu varijantu, preko poveznice.
3. Polipeptid prema patentnom zahtjevu 1, naznačen time što je prva nukleazna domena operativno povezana na N-terminalni kraj albumina, ili njegovu varijantu ili ulomak, i druga nukleazna domena je operativno povezana na C-terminalni kraj albumina, ili njegovu varijantu ili ulomak, poželjno pri čemu su prva i druga nukleazna domena operativno povezane na odgovarajuće N- i C-terminalne krajeve, albumina, ili njegovu varijantu ili ulomak, preko poveznice.
4. Polipeptid prema patentnom zahtjevu 1, naznačen time što je prva nukleazna domena operativno povezana na drugu nukleaznu domenu preko poveznice, i druga nukleazna domena je operativno povezana na albumin, ili njegovu varijantu ili ulomak, poželjno pri čemu je druga nukleazna domena operativno povezana na N-terminalni kraj albumina, ili njegovu varijantu ili ulomak ili poželjno pri čemu je druga nukleazna domena operativno povezana na C-terminalni kraj albumina, ili njegovu varijantu ili ulomak.
5. Polipeptid prema bilo kojem od patentnih zahtjeva 1-4, naznačen time što je RNaza humana RNaza divljeg tipa, kao što je humana RNaza1 gušterače kao što je navedeno u SEQ ID NO: 75, ili mutirajuća RNaza, kao što je aglikozilirana ili podglikozilirana RNaza1, kao što je humana RNaza1 N34S/N76S/N88S prikazana kao SEQ ID NO: 84.
6. Polipeptid prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što razgrađuje cirkulirajuću RNA i/ili DNA i RNA i/ili DNA u imunološkim kompleksima, ili inhibira proizvodnju interferona, ili oboje.
7. Polipeptid prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što domena poveznice je polipeptidna poveznica, kao što je poveznica gly-ser, ili pri čemu domena poveznice je NLG poveznica.
8. Polipeptid prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što albumin, ili njegova varijantu ili ulomak, povećava poluživot u serumu.
9. Polipeptid prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je albumin, ili njegova varijanta ili ulomak, izveden iz ljudskog serumskog albumina, serumskog albumina primata, serumskog albumina glodavca, goveđeg serumskog albumina, konjskog serumskog albumina, kozjeg serumskog albumina, ovčjeg serumskog albumina, psećeg serumskog albumina, serumskog albumina zamorca, pilećeg serumskog albumina, ili svinjskog serumskog albumina, poželjno pri čemu je albumin, ili njegova varijanta ili ulomak, izveden iz ljudskog serumskog albumina, poželjno pri čemu je albumin više od 85% identičan odgovarajućoj aminokiselinskoj sekvenci prikazanoj u SEQ ID NO: 1, poželjno pri čemu je albumin, ili njegova varijanta ili ulomak, više od 90% identičan odgovarajućoj aminokiselinskoj sekvenci prikazanoj u SEQ ID NO: 1, poželjno pri čemu je albumin, ili njegova varijanta ili ulomak, više od 95% identičan odgovarajućoj aminokiselinskoj sekvenci prikazanoj u SEQ ID NO: 1.
10. Polipeptid prema patentnom zahtjevu 9, naznačen time što se varijanta ili ulomak ljudskog serumskog albumina veže na FcRn s većim afinitetom od onog za odgovarajući divlji tip ljudskog serumskog albumina ili njegovog ulomka.
11. Polipeptid prema patentnom zahtjevu 1 naznačen time što sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO: 112-114 ili 120-122, ili hibridnu molekulu nukleaza-albumin koja sadrži aminokiselinsku sekvencu najmanje 90% identičnu aminokiselinskoj sekvenci navedenoj u SEQ ID NO: 112-114 ili 120-122.
12. Pripravak naznačen time što sadrži polipeptid prema bilo kojem od prethodnih zahtjeva i nosač.
13. Molekula nukleinske kiseline naznačena time što kodira po polipeptid prema bilo kojem od zahtjeva 1 do 10.
14. Rekombinantni ekspresijski vektor naznačen time što sadrži molekulu nukleinske kiseline u skladu sa zahtjevom 13.
15. Stanica domaćina naznačena time što je transformirana s rekombinantnim ekspresijskim vektorom prema zahtjevu 14.
16. Postupak za proizvodnju polipeptida prema bilo kojem od patentnih zahtjeva 1-11, naznačen time što obuhvaća: osiguravanje stanice domaćina koja sadrži sekvencu nukleinske kiseline koja kodira polipeptid; i održavanje stanice domaćina u uvjetima u kojima se eksprimira hibridna molekula nukleaze-albumina.
17. Polipeptid prema bilo kojem od patentnih zahtjeva 1-11 ili pripravak prema zahtjevu 12 naznačen time što je za uporabu u liječenju ili prevenciji sistemskog eritemskog lupusa (SLE).
18. Polipeptid prema bilo kojem od patentnih zahtjeva 1-11 ili pripravak prema zahtjevu 12 naznačen time što je za uporabu u liječenju ili prevenciji Sjogrenovog sindroma.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898384P | 2013-10-31 | 2013-10-31 | |
| US201361898393P | 2013-10-31 | 2013-10-31 | |
| US201361898370P | 2013-10-31 | 2013-10-31 | |
| EP14802986.1A EP3063275B1 (en) | 2013-10-31 | 2014-10-31 | Therapeutic nuclease-albumin fusions and methods |
| PCT/US2014/063572 WO2015066550A1 (en) | 2013-10-31 | 2014-10-31 | Therapeutic nuclease-albumin fusions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192080T1 true HRP20192080T1 (hr) | 2020-02-07 |
Family
ID=51982759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192080TT HRP20192080T1 (hr) | 2013-10-31 | 2019-11-19 | Terapeutske fuzije nukleaza-albumine i postupci |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10988745B2 (hr) |
| EP (1) | EP3063275B1 (hr) |
| DK (1) | DK3063275T3 (hr) |
| ES (1) | ES2759252T3 (hr) |
| HR (1) | HRP20192080T1 (hr) |
| PL (1) | PL3063275T3 (hr) |
| SI (1) | SI3063275T1 (hr) |
| WO (2) | WO2015066550A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3460056T (lt) | 2009-11-02 | 2020-12-28 | University Of Washington | Terapinės nukleazės kompozicijos ir būdai |
| CN113005148A (zh) | 2013-01-16 | 2021-06-22 | 爱默蕾大学 | Cas9-核酸复合物及其相关用途 |
| DK3063275T3 (da) * | 2013-10-31 | 2019-11-25 | Resolve Therapeutics Llc | Terapeutiske nuklease-albumin-fusioner og fremgangsmåder |
| US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
| WO2017044424A1 (en) * | 2015-09-08 | 2017-03-16 | Theripion, Inc. | Apoa-1 fusion polypeptides and related compositions and methods |
| RU2018146050A (ru) * | 2016-05-27 | 2020-06-29 | Эббви Байотерапьютикс Инк. | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген |
| CA3029627A1 (en) * | 2016-07-01 | 2018-01-04 | Resolve Therapeutics, Llc | Optimized binuclease fusions and methods |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| CA3073317A1 (en) | 2017-08-18 | 2019-02-21 | Neutrolis Therapeutics, Inc. | Engineered dnase enzymes and use in therapy |
| JP2021510539A (ja) * | 2018-01-16 | 2021-04-30 | シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | デオキシリボヌクレアーゼ（ＤＮａｓｅ）活性を有する酵素の肝臓発現による疾患の処置 |
| CN110386984B (zh) * | 2018-04-17 | 2022-04-22 | 杭州尚健生物技术有限公司 | 结合cd47蛋白的融合蛋白及其应用 |
| US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| US11058724B2 (en) | 2018-10-08 | 2021-07-13 | Neutrolis, Inc. | Methods of using DNASE1-like 3 in therapy |
| SG11202103426XA (en) | 2018-10-08 | 2021-05-28 | Neutrolis Inc | Engineering of dnase enzymes for manufacturing and therapy |
| WO2020163264A1 (en) * | 2019-02-04 | 2020-08-13 | Neutrolis, Inc. | Engineered human extracellular dnase enzymes for drug candidate selection |
| US11352613B2 (en) | 2019-02-04 | 2022-06-07 | Neutrolis, Inc. | Engineered human extracellular DNASE enzymes |
| EP4041880A4 (en) * | 2019-10-07 | 2023-08-30 | Texas Tech University System | MUTANT DNASE1L3 WITH IMPROVED SERUM HALF-LIFE |
| AU2021205976A1 (en) * | 2020-01-11 | 2022-07-07 | Yale University | Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with DNAse1 and/or DNAse1L3 deficiency |
| US20230072226A1 (en) * | 2020-02-20 | 2023-03-09 | Neutrolis, Inc. | Basic domain-deleted dnase1-like 3 and uses thereof |
| AU2021288567A1 (en) * | 2020-06-08 | 2023-02-09 | Yale University | Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections |
| CN112480247B (zh) * | 2020-11-10 | 2023-09-22 | 华通福源生物技术(北京)股份有限公司 | 抗人血清白蛋白单克隆抗体 |
Family Cites Families (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1136039A (en) * | 1966-10-12 | 1968-12-11 | Nat Res Dev | Improvements relating to immunosuppressive agents |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US5453269A (en) | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5559212A (en) | 1988-04-06 | 1996-09-24 | Alfacell Corporation | Frog embryo and egg-derived tumor cell anti-proliferation protein |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| DE68929551T2 (de) * | 1988-12-23 | 2008-03-06 | Genentech, Inc., South San Francisco | Menschliche DNase |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5840840A (en) | 1990-04-17 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Selective RNase cytotoxic reagents |
| US6825037B1 (en) * | 1991-02-08 | 2004-11-30 | University Of Vermont | Recombinant transferrins, transferrin half-molecules and mutants thereof |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| GB9300686D0 (en) | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
| US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
| SK284191B6 (sk) * | 1995-02-24 | 2004-10-05 | Genentech, Inc. | Aktín-rezistentný variant humánnej DNázy I |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
| BR9606706A (pt) | 1995-10-16 | 1999-04-06 | Unilever Nv | Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo |
| US6482626B2 (en) | 1996-02-05 | 2002-11-19 | Genentech, Inc. | Human DNase |
| US6716974B1 (en) | 1996-05-31 | 2004-04-06 | Maine Medical Center Research Institute | Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| US7247302B1 (en) | 1996-08-02 | 2007-07-24 | Bristol-Myers Squibb Company | Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| EP0918872B1 (en) | 1996-08-02 | 2008-02-20 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| AU729515B2 (en) | 1996-10-17 | 2001-02-01 | Immunomedics Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US20030060407A1 (en) | 1997-06-16 | 2003-03-27 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20020192659A1 (en) | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6280991B1 (en) | 1997-10-15 | 2001-08-28 | Wisconsin Alumni Research Foundation | Engineered cytotoxic ribonclease |
| US5840296A (en) | 1997-10-15 | 1998-11-24 | Raines; Ronald T. | Engineered cytotoxic ribonuclease A |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US6239257B1 (en) | 1998-12-30 | 2001-05-29 | Alfacell Corporation | Family of proteins belonging to the pancreatic ribonuclease a superfamily |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2377731A1 (en) | 1999-07-02 | 2001-01-11 | Genentech, Inc. | Fusion peptides comprising a peptide ligand domain and a multimerization domain |
| US6175003B1 (en) | 1999-09-10 | 2001-01-16 | Alfacell Corporation | Nucleic acids encoding ribonucleases and methods of making them |
| US7118751B1 (en) | 1999-10-14 | 2006-10-10 | Trubion Pharmaceuticals, Inc. | DNA vaccines encoding antigen linked to a domain that binds CD40 |
| AU2001259063A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
| CA2436092A1 (en) | 2001-01-29 | 2002-08-08 | Idec Pharmaceutical Corporation | Modified antibodies and methods of use |
| CN1330664C (zh) | 2001-03-07 | 2007-08-08 | 默克专利有限公司 | 用于含杂合同种型抗体部分的蛋白质的表达技术 |
| JP4586310B2 (ja) | 2001-07-04 | 2010-11-24 | 株式会社Ｉｈｉ | セラミックス複合部材の製造方法 |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| US20060040262A1 (en) | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| AU2003209446B2 (en) | 2002-03-01 | 2008-09-25 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| US7098016B2 (en) | 2002-06-14 | 2006-08-29 | Wisconsin Alumni Research Foundation | Ribonuclease zymogen design |
| ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
| DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003284357A1 (en) | 2002-11-01 | 2004-06-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
| WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US7067298B2 (en) | 2003-03-31 | 2006-06-27 | Ambion, Inc. | Compositions and methods of using a synthetic Dnase I |
| US7666417B2 (en) | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
| US9051373B2 (en) * | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| CN1871259A (zh) | 2003-08-22 | 2006-11-29 | 比奥根艾迪克Ma公司 | 具有改变的效应物功能的经改进的抗体和制备它的方法 |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| DK1699821T3 (da) | 2003-12-31 | 2012-07-16 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER |
| BRPI0506771A (pt) | 2004-01-12 | 2007-05-22 | Applied Molecular Evolution | anticorpo, e, composição farmacêutica |
| US7544487B2 (en) | 2004-02-13 | 2009-06-09 | Immunomedics, Inc. | Fusion proteins containing recombinant cytotoxic RNAses |
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005115477A2 (en) * | 2004-04-13 | 2005-12-08 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| CN101987870B (zh) | 2004-07-15 | 2013-07-03 | 赞科股份有限公司 | 优化的Fc变体 |
| MX2007001638A (es) | 2004-08-11 | 2009-02-12 | Trubion Pharmaceuticals Inc | Proteinas de fusion del dominio de unión. |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| DE102005009219A1 (de) | 2005-02-25 | 2006-08-31 | Martin-Luther-Universität Halle-Wittenberg | Ribonuclease-Tandemenzyme und Verfahren zu ihrer Herstellung |
| US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| EP1888649A2 (en) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
| US7655757B2 (en) | 2005-06-16 | 2010-02-02 | Wisconsin Alumni Research Foundation | Cytotoxic ribonuclease variants |
| US7416875B2 (en) | 2005-06-16 | 2008-08-26 | Wisconsin Alumni Research Foundation | Cytotoxic ribonuclease variants |
| PT2298815E (pt) | 2005-07-25 | 2015-07-16 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
| US20080279850A1 (en) | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| TW200732472A (en) | 2005-10-21 | 2007-09-01 | Hoffmann La Roche | Method for the recombinant expression of a polypeptide |
| CN101466733A (zh) | 2006-04-14 | 2009-06-24 | 特鲁比昂药品公司 | 包含免疫球蛋白铰链区和Fc效应子功能改变了的Fc区的结合蛋白 |
| WO2007122511A2 (en) | 2006-04-21 | 2007-11-01 | Mab-Factory Gmbh | Antibody-rnase-conjugate |
| GB0611444D0 (en) | 2006-06-09 | 2006-07-19 | Medical Res Council Technology | Rnase H2 complex and genes therefor |
| MX2008015524A (es) | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| JP5102833B2 (ja) | 2006-07-24 | 2012-12-19 | バイオレクシス ファーマシューティカル コーポレーション | エキセンディン融合タンパク質 |
| US8198063B1 (en) | 2006-09-12 | 2012-06-12 | Pro Zyme, Inc | Rapid deglycosylation of glycoproteins |
| EP1905841A1 (en) | 2006-09-25 | 2008-04-02 | Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; | Trex1 as a marker for lupus erythematosus |
| US20080260738A1 (en) | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
| US20090258005A1 (en) | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
| BRPI0812562A2 (pt) | 2007-06-12 | 2019-09-24 | Trubion Pharmaceuticals Inc | composições terapêuticas anti-cd20 e métodos |
| BRPI0814060A2 (pt) | 2007-07-06 | 2015-01-06 | Trubion Pharmaceuticals Inc | Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal |
| WO2009015345A1 (en) | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
| BRPI0814465B1 (pt) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica |
| WO2009019314A1 (en) | 2007-08-08 | 2009-02-12 | Novozymes A/S | Transferrin variants and conjugates |
| WO2009051717A2 (en) | 2007-10-15 | 2009-04-23 | The University Of North Carolina At Chapel Hill | Human factor ix variants with an extended half life |
| WO2009064777A2 (en) | 2007-11-13 | 2009-05-22 | Sapphire Energy, Inc. | Production of fc-fusion polypeptides in eukaryotic algae |
| EP2082805A1 (en) | 2008-01-28 | 2009-07-29 | Basf Se | Process for the preparation of an aqueous colloidal precious metal suspension |
| WO2009126944A1 (en) | 2008-04-11 | 2009-10-15 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| EP2344674A4 (en) | 2008-09-26 | 2012-11-07 | Hoffmann La Roche | METHODS OF TREATING, DIAGNOSING, AND MONITORING LUPUS |
| WO2010039985A1 (en) | 2008-10-01 | 2010-04-08 | Quintessence Biosciences, Inc. | Therapeutic Ribonucleases |
| US9493545B2 (en) | 2009-02-11 | 2016-11-15 | Albumedix A/S | Albumin variants and conjugates |
| US8748380B2 (en) | 2009-10-30 | 2014-06-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| LT3460056T (lt) | 2009-11-02 | 2020-12-28 | University Of Washington | Terapinės nukleazės kompozicijos ir būdai |
| CN102770458A (zh) | 2009-12-02 | 2012-11-07 | 阿塞勒隆制药公司 | 用于增加Fc融合蛋白的血清半寿期的组合物和方法 |
| US20110221962A1 (en) | 2010-03-10 | 2011-09-15 | Microsoft Corporation | Augmented reality via a secondary channel |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| WO2012012020A1 (en) | 2010-07-20 | 2012-01-26 | Alcon Research, Ltd. | Drug delivery device with active iris |
| WO2012116274A2 (en) | 2011-02-25 | 2012-08-30 | Recombinetics, Inc. | Genetically modified animals and methods for making the same |
| SI3505528T1 (sl) | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulacija izražanja virusa hepatitisa B (HBV) |
| KR102596953B1 (ko) | 2011-04-29 | 2023-11-02 | 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 | 치료적 뉴클레아제 조성물 및 방법 |
| US20140178479A1 (en) | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| WO2013180295A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電信電話株式会社 | パケット転送処理方法およびパケット転送処理装置 |
| DK3063275T3 (da) * | 2013-10-31 | 2019-11-25 | Resolve Therapeutics Llc | Terapeutiske nuklease-albumin-fusioner og fremgangsmåder |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2014
- 2014-10-31 DK DK14802986T patent/DK3063275T3/da active
- 2014-10-31 WO PCT/US2014/063572 patent/WO2015066550A1/en active Application Filing
- 2014-10-31 EP EP14802986.1A patent/EP3063275B1/en active Active
- 2014-10-31 ES ES14802986T patent/ES2759252T3/es active Active
- 2014-10-31 PL PL14802986T patent/PL3063275T3/pl unknown
- 2014-10-31 SI SI201431413T patent/SI3063275T1/sl unknown
- 2014-10-31 WO PCT/US2014/063587 patent/WO2015066557A1/en active Application Filing
- 2014-10-31 US US15/032,581 patent/US10988745B2/en active Active
-
2019
- 2019-11-19 HR HRP20192080TT patent/HRP20192080T1/hr unknown
-
2021
- 2021-03-30 US US17/217,912 patent/US20210355462A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3063275A1 (en) | 2016-09-07 |
| SI3063275T1 (sl) | 2020-02-28 |
| US20160251638A1 (en) | 2016-09-01 |
| WO2015066550A1 (en) | 2015-05-07 |
| US10988745B2 (en) | 2021-04-27 |
| ES2759252T3 (es) | 2020-05-08 |
| WO2015066557A1 (en) | 2015-05-07 |
| US20210355462A1 (en) | 2021-11-18 |
| PL3063275T3 (pl) | 2020-03-31 |
| EP3063275B1 (en) | 2019-09-25 |
| DK3063275T3 (da) | 2019-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192080T1 (hr) | Terapeutske fuzije nukleaza-albumine i postupci | |
| HRP20221089T1 (hr) | Optimizirani geni faktora viii | |
| MY176331A (en) | Carbohydrate degrading polypeptide and uses thereof | |
| JP2019506166A5 (hr) | ||
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| JP2018537087A5 (hr) | ||
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| MX2019006349A (es) | Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas. | |
| JP2019536462A5 (hr) | ||
| JP2015525217A5 (hr) | ||
| FI3677591T3 (fi) | Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b | |
| TR201820102T4 (tr) | Fabri hastalığı gen tedavisi. | |
| UA98620C2 (uk) | Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2 | |
| MX2011011215A (es) | Polipeptido que degrada carbohidratos y usos del mismo. | |
| MY160897A (en) | Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof | |
| EA201300054A1 (ru) | Полипептид, обладающий активностью бета-глюкозидазы, и его применение | |
| PE20171652A1 (es) | Nuevas proteinas especificas para pioverdina y pioquelina | |
| MX2017010880A (es) | Variantes de polipéptidos para el clivaje de la toxina fusario, aditivo que contiene las mismas, uso de las mismas, y método para el clivaje de las toxinas fusario. | |
| NZ705575A (en) | Recombinant clostridium botulinum neurotoxins | |
| JP2009517340A5 (hr) | ||
| JP2015524403A5 (hr) | ||
| JP2015500827A5 (hr) | ||
| NZ781138A (en) | Anti-vegf protein compositions and methods for producing the same | |
| JP2015500864A5 (hr) | ||
| EA201300056A1 (ru) | Полипептид с активностью ацетилксиланэстеразы и его применения |